Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy.
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy.
复制标题
DOI：
10.1002/cpt.583
复制
发表时间：
2017-07
影响因子：
6.7
通讯作者：
Walsh TJ
中科院分区：
文献类型：
--
作者：
Moriyama B;Obeng AO;Barbarino J;Penzak SR;Henning SA;Scott SA;Agúndez J;Wingard JR;McLeod HL;Klein TE;Cross SJ;Caudle KE;Walsh TJ
伏立康唑是一种三唑类抗真菌药，其血清浓度存在广泛的患者间变异性，部分原因是CYP 2C 19等位基因变异。CYP 2C 19超快代谢型个体的伏立康唑谷浓度降低，延迟达到目标血药浓度;而慢代谢型个体的伏立康唑谷浓度升高，药物不良事件风险增加。我们总结了支持这种关联的文献证据，并根据CYP 2C 19基因型提供了使用伏立康唑治疗的治疗建议（更新见https://cpicpgx.org/guidelines/和www.pharmgkb.org）。
Voriconazole, a triazole antifungal agent, demonstrates wide interpatient variability in serum concentrations, due in part to variant CYP2C19 alleles. Individuals who are CYP2C19 ultrarapid metabolizers have decreased trough voriconazole concentrations, delaying achievement of target blood concentrations; whereas, poor metabolizers have increased trough concentrations and are at increased risk of adverse drug events. We summarize evidence from the literature supporting this association and provide therapeutic recommendations for the use of voriconazole for treatment based on CYP2C19 genotype (updates at https://cpicpgx.org/guidelines/ and www.pharmgkb.org).